Compare GSK plc (GSK) vs Prologis Inc (PLD) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Prologis Inc — how do they compare? GSK plc trades at $50.34 (market cap $101.13B), while Prologis Inc trades at $140.19 (market cap $133.74B). The key difference: Prologis Inc is the larger of the two by market cap, and GSK plc pays the higher dividend (3.61%). Which is the better fit depends on your goals.
| GSK | PLD | |
|---|---|---|
Market Cap | $101.13B | $133.74B |
Sector | Health | Real Estate |
52-Week High | $61.18 | $149.96 |
52-Week Low | $38.96 | $105.44 |
Enterprise Value | $121.57B | $168.48B |
Dividend Yield | 3.61% | 3.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
Prologis (PLD) trades at $140.46, up 1.25% on the day, with a bearish technical signal but strong fundamentals. Recent earnings consistently beat estimates, and the company announced a major $18.8 billion acquisition of Segro (WSJ, 2026-08-04). Valuation ratios are elevated, with a P/E of 31.07 and P/S of 14.54, while profitability remains robust with a net income margin of 45.79%.
The outlook is mixed: analyst consensus is bullish with a $159.22 price target, but the Segro acquisition introduces integration risks and leverage concerns. Upside hinges on successful merger execution and sustained industrial real estate demand, while downside risks include debt load and economic slowdowns impacting logistics property valuations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Prologis Inc
Prologis was formed by the June 2011 merger of AMB Property and Prologis Trust. The company develops, acquires, and operates around 1 billion square feet of high-quality industrial and logistics facilities across the globe. The company also has a strategic capital business segment that has around $70 billion of third-party AUM. The company is organized into four global divisions (Americas, Europe, Asia, and other Americas) and operates as a real estate investment trust.
Read more on PLD →
